Overview of Imipen

Quick Facts

Property	Description
Active Ingredients	Imipenem, Cilastatin
Form	Sterile powder for solution for injection
Pharmacological Class	Carbapenem antibiotic
Origin	Synthetic
Route of Administration	Intravenous infusion

What Type of Medicine is Imipen (Imipenem/Cilastatin)?

Imipen is a potent, synthetic pharmaceutical defined as a fixed-dose combination product that belongs to the Carbapenem antibiotic class, a powerful subgroup of beta-lactam antimicrobials. This medication is clinically recognized for its essential role in treating widespread, severe systemic bacterial infections, serving as a reliable intervention in high-acuity medical settings. The core strength of the drug is its broad-spectrum capability, which allows it to target a wide variety of difficult-to-treat organisms. This drug provides a strong, comprehensive treatment option when multiple bacterial types may be involved in a severe infection, such as complex intra-abdominal conditions.

Composition: Why Does Imipen Contain Cilastatin?

The pharmaceutical composition is dual-action: Imipenem is the primary bactericidal agent that disrupts the bacterial cell wall, while Cilastatin acts as a protective shield. Cilastatin inhibits the renal enzyme dehydropeptidase-I (DHP-I), which would otherwise rapidly inactivate Imipenem within the kidneys. The necessity of this co-formulation underscores that the drug's activity relies on protecting its key component from the body's natural metabolic processes. This synergistic co-formulation ensures that high, effective concentrations of the antibiotic are maintained for delivery via parenteral administration (intravenous infusion).

What side effects are possible with Imipen?

Possible Side Effects and Safety Information

Imipen (Imipenem/Cilastatin) is associated with an established safety profile based on government regulatory documentation. The side effects are categorized by the body systems they affect and the frequency with which they are reported.

Adverse Reaction Scope

Category	Examples (Reported in Regulatory Documents)
Common Side Effects	Nausea, vomiting, diarrhea, rash, phlebitis (inflammation of the vein) or pain at the injection site.
System-Organ Classes (SOC)	Gastrointestinal Disorders, Nervous System Disorders, Skin and Subcutaneous Tissue Disorders, and Blood and Lymphatic System Disorders.
Serious Adverse Reactions	Seizures/Convulsions, severe hypersensitivity (allergic) reactions (including anaphylaxis), and Clostridium difficile-associated diarrhea (CDAD), which may range from mild diarrhea to fatal colitis.
CNS Safety	Central Nervous System (CNS) reactions like seizures, myoclonic activity (involuntary muscle jerks), and confusional states are reported, most commonly in patients with existing CNS disorders and/or compromised kidney function.

Safety-Related Restrictions and Considerations

Hypersensitivity: The medicine is contraindicated in patients with a known history of severe hypersensitivity to any component or to other beta-lactam antibiotics (e.g., penicillins or cephalosporins), as cross-sensitivity can occur.
Kidney Function: Patients with impaired renal function, or those with a history of seizures, have a higher risk of CNS adverse effects, and dosage adjustments are required in these populations.
Drug Interactions: Concomitant use with valproic acid or divalproex sodium is generally not recommended, as it may decrease the concentration of those drugs and increase the risk of breakthrough seizures.
Pediatric Use: The medication is not indicated for pediatric patients with Central Nervous System infections due to the risk of seizures.

This structured information details the risks and limitations of the medicine as formally defined in official regulatory labels, serving as the basis for understanding its risk profile.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Imipen (Imipenem/Cilastatin) overdose focuses primarily on severe central nervous system (CNS) effects, which are considered an exaggeration of known adverse reactions.

Category	Official Regulatory Statement
Documented overdose presentations	Clinical manifestations documented include seizures, tremors, and myoclonic activity, representing CNS excitability. Confusion, nausea, and vomiting are also listed as potential signs.
Physiological systems affected	The Central Nervous System (CNS) is the primary system noted for severe outcomes.
Population-specific overdose notes	Overdose risk and severity are officially noted as being increased in patients with renal impairment (e.g., creatinine clearance le 40 mL/min) and those with pre-existing CNS disorders.
Emergency-response statements	Individuals must seek immediate medical attention or contact emergency services upon any suspicion of overdose. Management is required to be symptomatic and supportive.
Overdose-context constraints	No specific antidote is known for the combination product. Haemodialysis is documented as a procedure that may be useful for facilitating the removal of the components from the body.

Official overdose statements:

The primary manifestations documented in regulatory texts are severe CNS effects, particularly the potential for seizures.
When severe symptoms occur, urgent medical attention is required, and close hospital monitoring is mandated.
The management strategy must address symptoms directly since the official label states that a specific antidote is not known.

Connection to the overall overdose profile: Regulatory documents define the overdose profile of Imipen by emphasizing the risk of severe CNS effects as the critical concern. This risk dictates the immediate requirement to seek urgent medical attention and underscores that patient management is confined to symptomatic and supportive care given the explicit statement that a specific antidote is not known.

Therapeutic Uses of Imipen

What Imipen treats: Main Uses and Benefits

Imipen is commonly used in situations involving severe, widespread infections like septicemia (blood infection) and other conditions presenting with high physiological stress. It is applied in addressing the infectious cause of persistent high fevers, chills, and rapid clinical deterioration, and is relevant for easing symptoms related to systemic inflammatory responses. The medication is officially indicated for the treatment of bacterial septicemia, among other severe conditions.

The medication is considered relevant for managing complicated infections in complex or deep anatomical sites, including severe intra-abdominal abscesses, hospital-acquired pneumonia, and extensive bone or deep skin infections. The primary therapeutic benefit is to support comprehensive bacterial clearance in challenging settings, which assists with managing symptoms that may become intense or disruptive. Imipen is commonly used to address conditions like endocarditis, gynecologic infections, and complicated urinary tract infections.

“This treatment is utilized to address infections caused by multidrug-resistant bacteria or following the clinical failure of prior antibiotics.”

It also provides crucial supportive relief for vulnerable patients, such as those with neutropenic fever, and is commonly used when short-term symptomatic assistance is needed in acute clinical settings. The use of Imipen supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.

Quick Fact: Relief for Systemic Discomfort

Symptom Domain	Use Case	Benefit
Systemic Fever	Severe bloodstream infections (sepsis)	Supports the management of symptoms related to high fever and chills.
Deep Tissue Pain	Complicated abscesses/bone infections	Applied in addressing pain related to deep tissue infections.
Functional Strain	High-risk (neutropenic) fever	Helps maintain a sense of stability when symptoms are more noticeable.

Regulatory References

NIH DailyMed Prescribing Information for Imipenem and Cilastatin

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Imipen

The eligibility profile for Imipen (Imipenem/Cilastatin) is strictly defined by regulatory authorities and centers on patient hypersensitivity, age, organ function, and neurological history.

Absolute Contraindications

Imipen is contraindicated and must not be administered to patients who have:

A known severe hypersensitivity or allergic reaction to Imipenem, Cilastatin, or any component of the formulation.
A history of severe allergic reactions to any other Carbapenem antibacterial agent.
A history of severe hypersensitivity (e.g., anaphylaxis) to any other beta-lactam antibiotic (such as penicillins or cephalosporins).

Age and Condition-Based Restrictions

Population Group	Regulatory Status / Restriction
Pediatric Patients < 3 Months	Use is not established due to insufficient clinical data.
Pediatric CNS Infections	Not recommended for the therapy of meningitis or other Central Nervous System (CNS) infections due to the risk of seizures.
Severe Renal Impairment	Not recommended if Creatinine Clearance (CrCl) is less than 15 mL/min, unless the patient is scheduled for hemodialysis within 48 hours.
CNS Disorders	Use requires special caution and careful monitoring in patients with pre-existing disorders, such as a history of seizures or brain lesions.
Pregnancy / Lactation	Use is generally advised only if the benefit to the mother is considered to outweigh the potential risk (as specific safety is often not fully established).

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Imipen (Imipenem/Cilastatin) is strictly defined by regulatory warnings concerning significant pharmacokinetic alteration and reinforced neurotoxic effects when co-administered with certain medicines. The structure establishes mandatory restrictions based on official documentation.

Contraindicated Combinations and Exposure Risks

Co-administration is generally not recommended or formally restricted for several drug classes:

Anticonvulsants (e.g., Valproic Acid, Divalproex Sodium): Combination is not recommended because Imipen reduces the plasma concentration of Valproic Acid. This effect, linked to an enzyme-mediated inhibition of metabolite hydrolysis, can result in inadequate seizure control.
Antivirals (e.g., Ganciclovir, Valganciclovir): Concomitant use should not be used unless the benefit outweighs the risks, as the combination is strongly associated with an increased incidence of generalized seizures.
Renal Clearance Inhibitors (e.g., Probenecid): Co-administration is not recommended due to a transporter-mediated interaction where Probenecid inhibits the renal tubular secretion of both Imipenem and Cilastatin. This results in significantly increased plasma levels and prolonged systemic exposure.

Pharmacodynamic and Population-Specific Interactions

Neurotoxic Reinforcement: The risk of neurotoxic effects may be increased with other agents, such as Cyclosporine. These risks may be heightened in patients with pre-existing central nervous system disorders or compromised renal function.
Vaccine Antagonism: The antibacterial action of Imipen can antagonize the therapeutic effect of Live Bacterial Vaccines, such as the oral Cholera Vaccine.

No specific mandatory timing separation rules are documented for Imipen, and no restrictive interaction patterns with food, alcohol, or common herbal products are explicitly cited in official regulatory documents.

Mechanism of Action

How Imipenem Works

Disruption of Bacterial Structural Integrity

Imipenem acts as an irreversible inhibitor that targets the essential bacterial enzymes known as Penicillin-Binding Proteins (PBPs), which are responsible for constructing the rigid bacterial cell wall. This mechanism prevents the final cross-linking of the peptidoglycan layer, which is essential for maintaining the bacterium's structure. The resulting physiological effect is the rapid, irreversible breakdown and rupture (lysis) of the bacterial cell due to internal osmotic pressure, leading to the loss of structural integrity.

Protection from Metabolic Clearance

The co-administered ingredient, cilastatin, plays a mechanistic role not by targeting the bacteria, but by protecting imipenem from human enzymes. Cilastatin acts as an inhibitor of the renal enzyme Dehydropeptidase-I (DHP-I), which would otherwise quickly break down imipenem in the kidney. Cilastatin blocks the enzyme, which facilitates maintaining active imipenem availability in the systemic circulation to engage its bacterial targets and produce the resulting physiological effect.

Dosage and Administration Information

How to Use Imipen

Imipenem/Cilastatin is administered solely through Intravenous (IV) Infusion, requiring a hospital or specialized clinical setting for its preparation and delivery. The medication is provided as a sterile powder that must be reconstituted and diluted prior to use to ensure proper systemic delivery.

Standard Administration Schedule and Dosing

The dosage schedule is based on the Imipenem component and is typically divided into three to four equally-split doses daily. Standard adult regimens include 500 mg IV every 6 hours or 1 g IV every 8 hours, depending on the severity of the condition. The maximum dose administered in a single day must not exceed 4 g. The total course of therapy generally spans 4 to 14 days, guided by the clinical response.

Procedural Administration and Adjustments

Category	Procedural Instruction
Infusion Time	Doses up to 500 mg must be infused over 20 to 30 minutes. Doses of 1 g must be infused over 40 to 60 minutes.
Infusion Rate	If a patient experiences intolerance during the infusion, the rate of administration may be slowed as needed.
Renal Impairment	Dose reduction and/or extension of the dosing interval is mandatory for patients with reduced kidney function (creatinine clearance <90 mL/min).
Hemodialysis	Administration should occur after a hemodialysis session to account for drug removal.

These explicit instructions define the standardized procedural steps for the medicine, ensuring its precise delivery and adherence to standardized parameters for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Imipen

This section provides a factual overview of the clinical research and scientific evidence that has been gathered for Imipen (Imipenem/Cilastatin), describing the types of studies conducted and the outcomes that researchers measured, without offering any clinical advice.

Evidence for Severe Intra-Abdominal and Urinary Tract Infections

The research base for Imipen in severe, deep-seated infections relies heavily on Randomized Controlled Trials (RCTs), where patients were randomly assigned to different study groups. These studies primarily focused on measuring short-term outcomes related to the acute infection.

Imipen was studied for use in hospitalized adults enrolled in research protocols for complicated intra-abdominal infections (cIAI). Researchers examined outcomes related to systemic or functional imbalance, specifically Clinical Response (a defined endpoint of change or resolution at the end of treatment). Findings describe patterns observed regarding the short-term course of the acute infection phase. Results apply only to the populations studied, and follow-up durations were limited to short intervals.

For complicated urinary tract infections (cUTI), clinical research explored Imipen in hospitalized adults. Studies monitored outcomes such as Microbiological Eradication, which is the measured absence of bacteria from the urine, and the measurement of symptom evolution. Research focusing on episodes where symptoms become more noticeable after the immediate recovery period—meaning long-term recurrence rates—is generally insufficient.

Evidence in Special Patient Populations and Research Gaps

The defining research for Imipen primarily included adult populations with moderate to severe disease, meaning data for certain groups remain insufficient. For example, evidence is limited for very specific age groups, such as the pediatric population, or for the elderly with extensive underlying health conditions.

The body of research does highlight areas where certainty remains low or where research is ongoing. Evidence quality varies across studies, particularly for the broader indications (like septicemia), where reliance is often placed on older or observational studies rather than dedicated, recent RCTs. Furthermore, comparative evidence is lacking for every possible antibiotic combination, meaning research provides context but not individual predictions for treatment choice in all clinical scenarios.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Imipen (FAQ)

Q: Why is Imipen only available in a hospital setting or by injection?

The official product information states that this medication is a sterile powder that must be reconstituted and diluted by a healthcare professional before it can be used. Since it is only administered through an intravenous (IV) infusion over a specific time period (20 to 60 minutes), this procedure requires a specialized clinical or hospital setting for proper preparation and delivery.

Q: Can Imipen cause insomnia or change sleep patterns?

The drug is associated with Central Nervous System (CNS) adverse reactions, which means it can affect the brain and nervous system. Official reports mention side effects such as confusional states and involuntary muscle jerks (myoclonic activity). Official guidance advises patients to consult their healthcare provider for medical evaluation if they experience changes in their mental state.

Q: Are there any long-term health issues linked to receiving multiple courses of Imipen?

Studies and official information indicate that clinical trial follow-up durations for Imipen were typically short-term. Therefore, the available research base on long-term recurrence rates or chronic effects associated with receiving multiple courses is currently limited and not fully established.

Q: Is Imipen considered a 'last-resort' antibiotic by medical professionals?

Official documents describe this medication as being indicated for the treatment of serious bacterial infections. It is specifically used for patients who have limited or no alternative treatment options available, which implies a reserved status for use in high-acuity medical settings.

Q: How long does Imipen stay in the patient's system after the final dose?

Information from the Pharmacokinetics section of the drug label indicates how the body processes the medicine. The elimination half-life of the imipenem component is approximately one hour, and most of the drug is typically cleared from the body through urine within about ten hours after the last administration.

Q: What are the most common signs of an allergic reaction to Imipen I should watch for?

Common signs of an allergic reaction reported in official documents include rash and itching. It is important to know that Imipen is associated with a risk of severe hypersensitivity reactions, which may involve serious signs like swelling of the face, tongue, or throat, or trouble breathing. Serious signs of a severe allergic reaction are generally managed as a medical emergency.

Q: What is the process for monitoring a patient during a course of Imipen?

Monitoring is mandatory for certain patient populations as defined in the official prescribing information. This includes patients with known reduced kidney function, where official guidance requires that the dosage be adjusted for these patients, and patients with pre-existing Central Nervous System (CNS) disorders, who are monitored closely due to the risk of seizures.

Q: Can Imipen interact with commonly prescribed blood thinners?

Yes, official drug interaction data indicates that Imipen may interact with certain anticoagulants (blood thinners). When these medicines are combined, there may be an increased risk or severity of bleeding.

Q: Are there any reports of Imipen causing confusion or hallucinations?

Reports include Central Nervous System reactions such as confusional states and involuntary muscle movements. Psychiatric disturbances and hallucinations have also been reported in the post-marketing surveillance setting.

Q: Does research show that Imipen affects the results of any common medical lab tests?

Changes in laboratory values have been reported. These changes can include temporary increases in liver enzymes (transaminases), BUN (a measure of kidney function), and creatinine. Changes in blood cell counts may also occur.

Q: What specific types of infections is Imipen primarily used to treat?

Studies and official information indicate that the drug is primarily used for serious infections caused by susceptible bacteria. Specifically, clinical studies focused on its effectiveness in treating complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

Q: Is it possible to develop a resistance to Imipen over time?

Official documents contain a warning about the development of drug-resistant bacteria. Regulatory warnings state that the drug should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. This measure is intended to help limit the development of drug resistance.

Q: Is it necessary to finish the entire course of Imipen even if I feel better?

Official patient counseling information for antibiotics advises that the drug is intended to be given for the entire course of treatment prescribed. This practice helps to fully clear the infection, even if symptoms begin to improve earlier.

Q: Can Imipen affect my mood or lead to anxiety?

The drug is associated with Central Nervous System (CNS) effects. Psychiatric disturbances, including agitation and confusion, have been reported in the post-marketing surveillance setting.

Q: What are the warning signs of liver problems associated with Imipen?

Official adverse reaction reports note that liver problems have been reported. This includes temporary increases in liver enzymes (transaminases). More serious reactions such as jaundice (yellowing of the skin or eyes) and hepatitis have been reported in post-marketing use.

Q: What does the FDA label say about Imipen's classification in terms of safety?

The official safety profile is defined by specific Contraindications (conditions where the drug must not be used, like severe hypersensitivity) and a list of Warnings and Precautions. These warnings concern risks such as the potential for seizures and Clostridium difficile-associated diarrhea (CDAD).

Q: Do studies suggest Imipen is more effective for some infections than others?

The clinical studies section of the drug label confirms that research was primarily focused on specific types of infections. Dedicated clinical trials concentrated on assessing its use and efficacy in treating complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Q: Is there a generic version of Imipen available?

Yes, official drug information from the National Institutes of Health (NIH) confirms that generic versions of the active ingredients, imipenem and cilastatin, are available from several manufacturers.

Q: How are side effects from Imipen reported or monitored officially?

Patient counseling information advises contacting the healthcare provider for medical advice about side effects. Serious or bothersome side effects can be reported to the relevant regulatory authority, such as the FDA via its MedWatch program, to contribute to official safety surveillance.

Q: What official body regulates the use and information about Imipen?

Regulatory information for this drug in the United States is officially published by the U.S. Food and Drug Administration (FDA). This information is publicly accessible through the National Institutes of Health (NIH) DailyMed service.

Q: Why is Imipen sometimes reserved for severe or multi-drug resistant infections?

The product information includes a warning that the drug should be used only for susceptible bacteria. This is a measure intended to help reduce the development of drug resistance and maintain the drug's effectiveness. It is also indicated for patients with serious infections where limited or no alternative treatment options are available.

How should Imipen be stored and disposed of?

How to Store and Dispose of Imipen

Storage and disposal of Imipen (Imipenem/Cilastatin) must strictly follow official regulatory guidelines to ensure stability and environmental safety.

Labeled Storage Conditions

Item	Official Requirement
Unopened Powder	Store at or below 25 C and protect from light.
Prepared Solution	Must be used immediately; the entire process, from reconstitution to end of infusion, must not exceed two hours.
Freezing	The prepared solution must not be frozen.
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired medicine must not be thrown away via wastewater or household waste. Disposal should be accomplished by consulting a pharmacist for guidance on safe discarding, a measure required to protect the environment.

Imipen